Please assess the completion status of the following clinical trial:

Trial Title: Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years~2. History of type 2 diabetes mellitus for at least 3 months~3. Prior therapy with dietary management, oral agents, or insulin~4. Non child-bearing potential or a negative urine pregnancy test~5. Initial blood glucose in ER \> 200 mg/dl~Exclusion Criteria:~1. Subsequent finding of diabetic ketoacidosis or hyperosmolar non-ketotic syndrome after initial evaluation.~2. Patients with critical illness suspected to require intensive care unit admission or direct surgical intervention.~3. History of current drug or alcohol abuse.~4. History of current mental illness~5. Inability to give informed consent~6. Female patients who are pregnant or are breast feeding~7. Patients who have clinically significant liver disease with AST/ALT (aspartate transaminase/alanine transaminase) \> 3 times the upper range of normal~8. Patients currently treated with dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- aspart detemir (Type: ACTIVE_COMPARATOR): these subjects will be treated with insulin aspart every 2 hours if blood glucose is more than 200 mg/dl during their ER evaluation. If they are admitted to hospital then they will receive a weight-based dose of insulin detemir immediately prior to admission and then every 24 hours thereafter combined with mealtime doses of insulin aspart if they are eating.
- usual care (Type: NO_INTERVENTION): these subjects will receive no insulin per protocol during their ER stay or during a possible inpatient admission. The care for their diabetes will be solely determined by the physician(s) in the ER and by the physician(s) caring for them in the hospital if they are admitted. They may receive no therapy, oral agents or insulin per primary physician preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).